 | • レポートコード：QYR2104Z0278 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、91ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、アルツハイマー病治療・診断のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（バイオマーカー、コリンエステラーゼ阻害剤、NMDA受容体拮抗薬、脳イメージング、血液検査）、用途別市場規模（医薬品市場、診断市場）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・アルツハイマー病治療・診断の市場動向 ・企業の競争状況、市場シェア ・アルツハイマー病治療・診断の種類別市場規模（バイオマーカー、コリンエステラーゼ阻害剤、NMDA受容体拮抗薬、脳イメージング、血液検査） ・アルツハイマー病治療・診断の用途別市場規模（医薬品市場、診断市場） ・アルツハイマー病治療・診断の北米市場規模2016-2027（アメリカ、カナダ） ・アルツハイマー病治療・診断のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・アルツハイマー病治療・診断のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・アルツハイマー病治療・診断の中南米市場規模2016-2027（メキシコ、ブラジル） ・アルツハイマー病治療・診断の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Namenda、Aricept、Exelon、Solanezumab、Gantenerumab、Verubecestat、Pfizer、Eisai、Actavis、Lundbeck、Daiichi Sankyo、Novartis、TauRx） ・結論 |
Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer’s disease worldwide emphasizing the necessity for developing an effective treatment. According to Alzheimer’s Association, in 2016, an estimated 5.4 million Americans of all ages have Alzheimer’s disease. One in nine people aged 65 and above has Alzheimer’s disease. By 2050, the number of people aged 65 and above affected with Alzheimer’s disease is expected to nearly triple, from 5.2 million to an expected 13.8 million, excluding the development of medical advances to avert or cure the disease. The mortality rates due to Alzheimer’s disease are quite high. Between 2000 and 2013, deaths due to heart disease, stroke and prostate cancer decreased 14%, 23% and 11%, respectively, while deaths from AD increased 71% in the U.S. Similarly, According to Alzheimer’s disease International in 2015, there are an estimated 46.8 million people worldwide living with dementia and is further expected to grow in future. Thus, there is an increasing in the demand for Alzheimer’s therapeutics and diagnostics worldwide.
Population aging across the globe is a major factor driving the market for Alzheimer’s therapeutics and diagnostics. Rising life expectancy is contributing to quick increases in number of aged population, and is associated with increased prevalence of chronic diseases like dementia. Therapies for AD offer temporary and uncertain improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease advancement. Thus, the magnitude of the affected population and lack of suitable and effective treatment offers an incredible opportunity for drug manufacturers. However, identification of the primary reasons and mechanisms involved in AD are is limited. Drug manufacturers have been unable to validate significant clinical benefits of treatment for a numerous of new compounds due to strict regulations. One of the significant trend observed in this market is collaboration of the existing players. Precisely, diagnostic technology companies are carefully trying to bring about effective biomarker technologies to support and improve the drug development process for potential drug candidates which is further expected to propel the demand.
Market Analysis and Insights: Global Alzheimer’s Disease Therapeutics and Diagnostics Market
The global Alzheimer’s Disease Therapeutics and Diagnostics market size is projected to reach US$ 6270.3 million by 2026, from US$ 4741.8 million in 2019, at a CAGR of 4.0% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Alzheimer’s Disease Therapeutics and Diagnostics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Alzheimer’s Disease Therapeutics and Diagnostics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Alzheimer’s Disease Therapeutics and Diagnostics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Alzheimer’s Disease Therapeutics and Diagnostics market.
Global Alzheimer’s Disease Therapeutics and Diagnostics Scope and Market Size
Alzheimer’s Disease Therapeutics and Diagnostics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Alzheimer’s Disease Therapeutics and Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Biomarkers
Cholinesterase inhibitors
NMDA receptor antagonists
Brain imaging
Blood tests
Segment by Application
Drugs Market
Diagnostics Market
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Namenda
Aricept
Exelon
Solanezumab
Gantenerumab
Verubecestat
Pfizer
Eisai
Actavis
Solanezumab
Gantenerumab
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Alzheimer’s Disease Therapeutics and Diagnostics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Biomarkers
1.2.3 Cholinesterase inhibitors
1.2.4 NMDA receptor antagonists
1.2.5 Brain imaging
1.2.6 Blood tests
1.3 Market by Application
1.3.1 Global Alzheimer’s Disease Therapeutics and Diagnostics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Drugs Market
1.3.3 Diagnostics Market
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Alzheimer’s Disease Therapeutics and Diagnostics Market Perspective (2016-2027)
2.2 Alzheimer’s Disease Therapeutics and Diagnostics Growth Trends by Regions
2.2.1 Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Alzheimer’s Disease Therapeutics and Diagnostics Historic Market Share by Regions (2016-2021)
2.2.3 Alzheimer’s Disease Therapeutics and Diagnostics Forecasted Market Size by Regions (2022-2027)
2.3 Alzheimer’s Disease Therapeutics and Diagnostics Industry Dynamic
2.3.1 Alzheimer’s Disease Therapeutics and Diagnostics Market Trends
2.3.2 Alzheimer’s Disease Therapeutics and Diagnostics Market Drivers
2.3.3 Alzheimer’s Disease Therapeutics and Diagnostics Market Challenges
2.3.4 Alzheimer’s Disease Therapeutics and Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Alzheimer’s Disease Therapeutics and Diagnostics Players by Revenue
3.1.1 Global Top Alzheimer’s Disease Therapeutics and Diagnostics Players by Revenue (2016-2021)
3.1.2 Global Alzheimer’s Disease Therapeutics and Diagnostics Revenue Market Share by Players (2016-2021)
3.2 Global Alzheimer’s Disease Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Alzheimer’s Disease Therapeutics and Diagnostics Revenue
3.4 Global Alzheimer’s Disease Therapeutics and Diagnostics Market Concentration Ratio
3.4.1 Global Alzheimer’s Disease Therapeutics and Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Alzheimer’s Disease Therapeutics and Diagnostics Revenue in 2020
3.5 Alzheimer’s Disease Therapeutics and Diagnostics Key Players Head office and Area Served
3.6 Key Players Alzheimer’s Disease Therapeutics and Diagnostics Product Solution and Service
3.7 Date of Enter into Alzheimer’s Disease Therapeutics and Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Alzheimer’s Disease Therapeutics and Diagnostics Breakdown Data by Type
4.1 Global Alzheimer’s Disease Therapeutics and Diagnostics Historic Market Size by Type (2016-2021)
4.2 Global Alzheimer’s Disease Therapeutics and Diagnostics Forecasted Market Size by Type (2022-2027)
5 Alzheimer’s Disease Therapeutics and Diagnostics Breakdown Data by Application
5.1 Global Alzheimer’s Disease Therapeutics and Diagnostics Historic Market Size by Application (2016-2021)
5.2 Global Alzheimer’s Disease Therapeutics and Diagnostics Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Alzheimer’s Disease Therapeutics and Diagnostics Market Size (2016-2027)
6.2 North America Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Type
6.2.1 North America Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Type (2016-2021)
6.2.2 North America Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Type (2022-2027)
6.2.3 North America Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Type (2016-2027)
6.3 North America Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Application
6.3.1 North America Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Application (2016-2021)
6.3.2 North America Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Application (2022-2027)
6.3.3 North America Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Application (2016-2027)
6.4 North America Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Country
6.4.1 North America Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Country (2016-2021)
6.4.2 North America Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Alzheimer’s Disease Therapeutics and Diagnostics Market Size (2016-2027)
7.2 Europe Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Type
7.2.1 Europe Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Type (2016-2021)
7.2.2 Europe Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Type (2022-2027)
7.2.3 Europe Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Type (2016-2027)
7.3 Europe Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Application
7.3.1 Europe Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Application (2016-2021)
7.3.2 Europe Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Application (2022-2027)
7.3.3 Europe Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Application (2016-2027)
7.4 Europe Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Country
7.4.1 Europe Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Country (2016-2021)
7.4.2 Europe Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Alzheimer’s Disease Therapeutics and Diagnostics Market Size (2016-2027)
8.2 Asia-Pacific Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Type
8.2.1 Asia-Pacific Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Type (2016-2027)
8.3 Asia-Pacific Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Application
8.3.1 Asia-Pacific Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Application (2016-2027)
8.4 Asia-Pacific Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Region
8.4.1 Asia-Pacific Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Alzheimer’s Disease Therapeutics and Diagnostics Market Size (2016-2027)
9.2 Latin America Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Type
9.2.1 Latin America Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Type (2016-2021)
9.2.2 Latin America Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Type (2022-2027)
9.2.3 Latin America Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Type (2016-2027)
9.3 Latin America Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Application
9.3.1 Latin America Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Application (2016-2021)
9.3.2 Latin America Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Application (2022-2027)
9.3.3 Latin America Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Application (2016-2027)
9.4 Latin America Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Country
9.4.1 Latin America Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Country (2016-2021)
9.4.2 Latin America Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Alzheimer’s Disease Therapeutics and Diagnostics Market Size (2016-2027)
10.2 Middle East & Africa Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Type
10.2.1 Middle East & Africa Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Type (2016-2027)
10.3 Middle East & Africa Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Application
10.3.1 Middle East & Africa Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Application (2016-2027)
10.4 Middle East & Africa Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Country
10.4.1 Middle East & Africa Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Alzheimer’s Disease Therapeutics and Diagnostics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Namenda
11.1.1 Namenda Company Details
11.1.2 Namenda Business Overview
11.1.3 Namenda Alzheimer’s Disease Therapeutics and Diagnostics Introduction
11.1.4 Namenda Revenue in Alzheimer’s Disease Therapeutics and Diagnostics Business (2016-2021)
11.1.5 Namenda Recent Development
11.2 Aricept
11.2.1 Aricept Company Details
11.2.2 Aricept Business Overview
11.2.3 Aricept Alzheimer’s Disease Therapeutics and Diagnostics Introduction
11.2.4 Aricept Revenue in Alzheimer’s Disease Therapeutics and Diagnostics Business (2016-2021)
11.2.5 Aricept Recent Development
11.3 Exelon
11.3.1 Exelon Company Details
11.3.2 Exelon Business Overview
11.3.3 Exelon Alzheimer’s Disease Therapeutics and Diagnostics Introduction
11.3.4 Exelon Revenue in Alzheimer’s Disease Therapeutics and Diagnostics Business (2016-2021)
11.3.5 Exelon Recent Development
11.4 Solanezumab
11.4.1 Solanezumab Company Details
11.4.2 Solanezumab Business Overview
11.4.3 Solanezumab Alzheimer’s Disease Therapeutics and Diagnostics Introduction
11.4.4 Solanezumab Revenue in Alzheimer’s Disease Therapeutics and Diagnostics Business (2016-2021)
11.4.5 Solanezumab Recent Development
11.5 Gantenerumab
11.5.1 Gantenerumab Company Details
11.5.2 Gantenerumab Business Overview
11.5.3 Gantenerumab Alzheimer’s Disease Therapeutics and Diagnostics Introduction
11.5.4 Gantenerumab Revenue in Alzheimer’s Disease Therapeutics and Diagnostics Business (2016-2021)
11.5.5 Gantenerumab Recent Development
11.6 Verubecestat
11.6.1 Verubecestat Company Details
11.6.2 Verubecestat Business Overview
11.6.3 Verubecestat Alzheimer’s Disease Therapeutics and Diagnostics Introduction
11.6.4 Verubecestat Revenue in Alzheimer’s Disease Therapeutics and Diagnostics Business (2016-2021)
11.6.5 Verubecestat Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Details
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Alzheimer’s Disease Therapeutics and Diagnostics Introduction
11.7.4 Pfizer Revenue in Alzheimer’s Disease Therapeutics and Diagnostics Business (2016-2021)
11.7.5 Pfizer Recent Development
11.8 Eisai
11.8.1 Eisai Company Details
11.8.2 Eisai Business Overview
11.8.3 Eisai Alzheimer’s Disease Therapeutics and Diagnostics Introduction
11.8.4 Eisai Revenue in Alzheimer’s Disease Therapeutics and Diagnostics Business (2016-2021)
11.8.5 Eisai Recent Development
11.9 Actavis
11.9.1 Actavis Company Details
11.9.2 Actavis Business Overview
11.9.3 Actavis Alzheimer’s Disease Therapeutics and Diagnostics Introduction
11.9.4 Actavis Revenue in Alzheimer’s Disease Therapeutics and Diagnostics Business (2016-2021)
11.9.5 Actavis Recent Development
11.10 Lundbeck
11.10.1 Lundbeck Company Details
11.10.2 Lundbeck Business Overview
11.10.3 Lundbeck Alzheimer’s Disease Therapeutics and Diagnostics Introduction
11.10.4 Lundbeck Revenue in Alzheimer’s Disease Therapeutics and Diagnostics Business (2016-2021)
11.10.5 Lundbeck Recent Development
11.11 Daiichi Sankyo
11.11.1 Daiichi Sankyo Company Details
11.11.2 Daiichi Sankyo Business Overview
11.11.3 Daiichi Sankyo Alzheimer’s Disease Therapeutics and Diagnostics Introduction
11.11.4 Daiichi Sankyo Revenue in Alzheimer’s Disease Therapeutics and Diagnostics Business (2016-2021)
11.11.5 Daiichi Sankyo Recent Development
11.12 Novartis
11.12.1 Novartis Company Details
11.12.2 Novartis Business Overview
11.12.3 Novartis Alzheimer’s Disease Therapeutics and Diagnostics Introduction
11.12.4 Novartis Revenue in Alzheimer’s Disease Therapeutics and Diagnostics Business (2016-2021)
11.12.5 Novartis Recent Development
11.13 TauRx
11.13.1 TauRx Company Details
11.13.2 TauRx Business Overview
11.13.3 TauRx Alzheimer’s Disease Therapeutics and Diagnostics Introduction
11.13.4 TauRx Revenue in Alzheimer’s Disease Therapeutics and Diagnostics Business (2016-2021)
11.13.5 TauRx Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Alzheimer's Disease Therapeutics and Diagnostics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Biomarkers
Table 3. Key Players of Cholinesterase inhibitors
Table 4. Key Players of NMDA receptor antagonists
Table 5. Key Players of Brain imaging
Table 6. Key Players of Blood tests
Table 7. Global Alzheimer's Disease Therapeutics and Diagnostics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Alzheimer's Disease Therapeutics and Diagnostics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Alzheimer's Disease Therapeutics and Diagnostics Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Alzheimer's Disease Therapeutics and Diagnostics Market Share by Regions (2016-2021)
Table 11. Global Alzheimer's Disease Therapeutics and Diagnostics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Alzheimer's Disease Therapeutics and Diagnostics Market Share by Regions (2022-2027)
Table 13. Alzheimer's Disease Therapeutics and Diagnostics Market Trends
Table 14. Alzheimer's Disease Therapeutics and Diagnostics Market Drivers
Table 15. Alzheimer's Disease Therapeutics and Diagnostics Market Challenges
Table 16. Alzheimer's Disease Therapeutics and Diagnostics Market Restraints
Table 17. Global Alzheimer's Disease Therapeutics and Diagnostics Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Alzheimer's Disease Therapeutics and Diagnostics Market Share by Players (2016-2021)
Table 19. Global Top Alzheimer's Disease Therapeutics and Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alzheimer's Disease Therapeutics and Diagnostics as of 2020)
Table 20. Ranking of Global Top Alzheimer's Disease Therapeutics and Diagnostics Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Alzheimer's Disease Therapeutics and Diagnostics Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Alzheimer's Disease Therapeutics and Diagnostics Product Solution and Service
Table 24. Date of Enter into Alzheimer's Disease Therapeutics and Diagnostics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share by Type (2016-2021)
Table 28. Global Alzheimer's Disease Therapeutics and Diagnostics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Alzheimer's Disease Therapeutics and Diagnostics Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share by Application (2016-2021)
Table 32. Global Alzheimer's Disease Therapeutics and Diagnostics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Alzheimer's Disease Therapeutics and Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Alzheimer's Disease Therapeutics and Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Alzheimer's Disease Therapeutics and Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Alzheimer's Disease Therapeutics and Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Alzheimer's Disease Therapeutics and Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Alzheimer's Disease Therapeutics and Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 64. Namenda Company Details
Table 65. Namenda Business Overview
Table 66. Namenda Alzheimer's Disease Therapeutics and Diagnostics Product
Table 67. Namenda Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 68. Namenda Recent Development
Table 69. Aricept Company Details
Table 70. Aricept Business Overview
Table 71. Aricept Alzheimer's Disease Therapeutics and Diagnostics Product
Table 72. Aricept Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 73. Aricept Recent Development
Table 74. Exelon Company Details
Table 75. Exelon Business Overview
Table 76. Exelon Alzheimer's Disease Therapeutics and Diagnostics Product
Table 77. Exelon Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 78. Exelon Recent Development
Table 79. Solanezumab Company Details
Table 80. Solanezumab Business Overview
Table 81. Solanezumab Alzheimer's Disease Therapeutics and Diagnostics Product
Table 82. Solanezumab Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 83. Solanezumab Recent Development
Table 84. Gantenerumab Company Details
Table 85. Gantenerumab Business Overview
Table 86. Gantenerumab Alzheimer's Disease Therapeutics and Diagnostics Product
Table 87. Gantenerumab Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 88. Gantenerumab Recent Development
Table 89. Verubecestat Company Details
Table 90. Verubecestat Business Overview
Table 91. Verubecestat Alzheimer's Disease Therapeutics and Diagnostics Product
Table 92. Verubecestat Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 93. Verubecestat Recent Development
Table 94. Pfizer Company Details
Table 95. Pfizer Business Overview
Table 96. Pfizer Alzheimer's Disease Therapeutics and Diagnostics Product
Table 97. Pfizer Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 98. Pfizer Recent Development
Table 99. Eisai Company Details
Table 100. Eisai Business Overview
Table 101. Eisai Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 102. Eisai Recent Development
Table 103. Actavis Company Details
Table 104. Actavis Business Overview
Table 105. Actavis Alzheimer's Disease Therapeutics and Diagnostics Product
Table 106. Actavis Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 107. Actavis Recent Development
Table 108. Lundbeck Company Details
Table 109. Lundbeck Business Overview
Table 110. Lundbeck Alzheimer's Disease Therapeutics and Diagnostics Product
Table 111. Lundbeck Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 112. Lundbeck Recent Development
Table 113. Daiichi Sankyo Company Details
Table 114. Daiichi Sankyo Business Overview
Table 115. Daiichi Sankyo Alzheimer's Disease Therapeutics and Diagnostics Product
Table 116. Daiichi Sankyo Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 117. Daiichi Sankyo Recent Development
Table 118. Novartis Company Details
Table 119. Novartis Business Overview
Table 120. Novartis Alzheimer's Disease Therapeutics and Diagnostics Product
Table 121. Novartis Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 122. Novartis Recent Development
Table 123. TauRx Company Details
Table 124. TauRx Business Overview
Table 125. TauRx Alzheimer's Disease Therapeutics and Diagnostics Product
Table 126. TauRx Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 127. TauRx Recent Development
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Alzheimer's Disease Therapeutics and Diagnostics Market Share by Type: 2020 VS 2027
Figure 2. Biomarkers Features
Figure 3. Cholinesterase inhibitors Features
Figure 4. NMDA receptor antagonists Features
Figure 5. Brain imaging Features
Figure 6. Blood tests Features
Figure 7. Global Alzheimer's Disease Therapeutics and Diagnostics Market Share by Application: 2020 VS 2027
Figure 8. Drugs Market Case Studies
Figure 9. Diagnostics Market Case Studies
Figure 10. Alzheimer's Disease Therapeutics and Diagnostics Report Years Considered
Figure 11. Global Alzheimer's Disease Therapeutics and Diagnostics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Alzheimer's Disease Therapeutics and Diagnostics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Alzheimer's Disease Therapeutics and Diagnostics Market Share by Regions: 2020 VS 2027
Figure 14. Global Alzheimer's Disease Therapeutics and Diagnostics Market Share by Regions (2022-2027)
Figure 15. Global Alzheimer's Disease Therapeutics and Diagnostics Market Share by Players in 2020
Figure 16. Global Top Alzheimer's Disease Therapeutics and Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alzheimer's Disease Therapeutics and Diagnostics as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Alzheimer's Disease Therapeutics and Diagnostics Revenue in 2020
Figure 18. Global Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share by Type (2016-2021)
Figure 19. Global Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share by Type (2022-2027)
Figure 20. North America Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Alzheimer's Disease Therapeutics and Diagnostics Market Share by Type (2016-2027)
Figure 22. North America Alzheimer's Disease Therapeutics and Diagnostics Market Share by Application (2016-2027)
Figure 23. North America Alzheimer's Disease Therapeutics and Diagnostics Market Share by Country (2016-2027)
Figure 24. United States Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Alzheimer's Disease Therapeutics and Diagnostics Market Share by Type (2016-2027)
Figure 28. Europe Alzheimer's Disease Therapeutics and Diagnostics Market Share by Application (2016-2027)
Figure 29. Europe Alzheimer's Disease Therapeutics and Diagnostics Market Share by Country (2016-2027)
Figure 30. Germany Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market Share by Region (2016-2027)
Figure 40. China Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Alzheimer's Disease Therapeutics and Diagnostics Market Share by Type (2016-2027)
Figure 48. Latin America Alzheimer's Disease Therapeutics and Diagnostics Market Share by Application (2016-2027)
Figure 49. Latin America Alzheimer's Disease Therapeutics and Diagnostics Market Share by Country (2016-2027)
Figure 50. Mexico Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Alzheimer's Disease Therapeutics and Diagnostics Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Alzheimer's Disease Therapeutics and Diagnostics Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Alzheimer's Disease Therapeutics and Diagnostics Market Share by Country (2016-2027)
Figure 56. Turkey Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Alzheimer's Disease Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Namenda Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021)
Figure 60. Aricept Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021)
Figure 61. Exelon Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021)
Figure 62. Solanezumab Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021)
Figure 63. Gantenerumab Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021)
Figure 64. Verubecestat Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021)
Figure 65. Pfizer Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021)
Figure 66. Eisai Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021)
Figure 67. Actavis Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021)
Figure 68. Lundbeck Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021)
Figure 69. Daiichi Sankyo Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021)
Figure 70. Novartis Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021)
Figure 71. TauRx Revenue Growth Rate in Alzheimer's Disease Therapeutics and Diagnostics Business (2016-2021)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed
世界のアルツハイマー病治療・診断市場規模・現状・予測（2021年-2027年） Alzheimers is a neurodegenerative disorder that mostly occurs with aging and is a leading cause of dementia. Alzheimers is one of the leading causes of death in the United States, with more than 5 million Americans diagnosed with this dreaded disease, in year 2014. Market Analysis and Insights: Glob…- 世界のアルツハイマー病診断市場規模・現状・予測（2021年-2027年） Alzheimer's disease (AD), also referred to simply asAlzheimer's, is a chronic neurodegenerative diseasethat usually starts slowly and worsens over time. It is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events (short-term memory loss). …
- 世界のアルツハイマー病診断市場規模・現状・予測（2021年-2027年） The diagnosis of alzheimer's disease is divided into three steps. The first step is to determine whether it is alzheimer's disease.The second step is to look for the cause, to look for biomarkers such as prolapidin-1, prolapidin-2 and the amyloid gene, amyloid deposition, or hippocampal volume or me…
- 世界のアルツハイマー病診断市場 2021：企業別、地域別、種類・用途別 The Alzheimer's Disease Diagnostic market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade …
- 世界のアルツハイマー病治療市場規模・現状・予測（2021年-2027年） Alzheimer’s disease is a neurodegenerative, progressive, non-reversible disorder. Alzheimer’s disease is caused due to abnormal functioning of brain cells i.e. failure of synaptic transmission, resulting in the loss of cognitive functions. Some of the signs and symptoms of alzheimer’s disease are me…